International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
By Shaji K. Kumar, B. Paiva, K. Anderson, B. Durie, O. Landgren, P. Moreau, N. Munshi, S. Lonial, J. Bladé, M. Mateos and 30 more. The Lancet Oncology, 2016
2,558 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/6921d973cd0e71157eadc452e3fa3dfea1e7db4c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, methodology): “Recent data show that MRD negative status (as estimated by next generation molecular methods or flow cytometry) has favorable prognostic value.(30) However, additional trials are needed to determine if changes in treatment need to be made based on MRD status.”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, methodology): “molecular methods or flow cytometry) has favorable prognostic value.(33) However, additional trials are needed to determine if changes in treatment need to be made based on MRD status.”
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, neutral): “tional Myeloma Working Group criteria (38).”